Trending Now
TSLA Investors needs a new CEO and stock buy program for...
Tesla Inc (NASDAQ:TSLA) Stock last traded at $150.23 USD, down a whooping -249.70 (-62.44%) year to date. There are several reasons for the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Spotlight on Delivery Stocks as Omicron Takes Center Stage (DELHY, TWOH,...
As the Omicron variant starts to take over the headline feed around Covid, investors are left with the need to diversify back...
MAKE IT MODERN
LATEST REVIEWS
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance
Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company focusing on liver and viral diseases, recently executed a 1-for-25 reverse stock split. This...
MAKE IT MODERN
PERFORMANCE TRAINING
Could Carbon Markets be approaching a Trillion-Dollar Valuation?
One of the most highly sought-after investment themes since the tech boom in the late 90s might be a sector to which...
Monopar Therapeutics’ (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial
Exciting news from the world of cancer research! Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharma company, has just released positive early data...
Ocugen Inc (NASDAQ:OCGN)’s partner Bharat Biotech rejected by Indian state
Ocugen Inc (NASDAQ:OCGN) is currently trading at $12.05 with a volume of over 52M shares.
Bharat Biotech's home...
Akero Therapeutics Inc. (NASDAQ: AKRO) Completes Enrolment in Phase 2b HARMONY Study Of Efrixifermin...
Akero Therapeutics Inc. (NASDAQ: AKRO) has announced the completion of enrolment in the Phase 2b HARMONY trial of its novel FGF21, Efruxifermin (EFX) for...
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces PALISADE-1 Phase 3 Study Findings in Which PH94B...
VistaGen Therapeutics Inc. (NASDAQ: VTGN) has revealed topline findings from the third phase PALISADE-1 study of PH94B for the treatment of acute social anxiety...
MAKE IT MODERN
